• News
  • Technology
  • Culture
  • Entertainment
  • Sport
  • Travel
  • Music
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Monday, January 30, 2023
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
ADVERTISEMENT
Home Health&Beauty

U.K. Rolls Out PRINCIPLE Trial to Evaluate Potential COVID-19 Treatments in the Community

by The FINANCIAL
May 16, 2020
in Health&Beauty
0
Share on FacebookShare on Twitter

RelatedPosts

Comparison of diuretics shows no difference in heart failure survival

Experimental HIV vaccine regimen safe but ineffective, study finds

Leading cause of death of care home residents in England

Study finds how much people would pay to live without food hypersensitivity

The FINANCIAL — Researchers at the University of Oxford are rolling out a U.K. trial to assess whether low-risk treatment in the community can help to reduce symptoms of COVID-19 in older patients, help them to recover more quickly, and so reduce the need for hospitalization. The Platform Randomized Trial of Interventions against COVID-19 in Older People (PRINCIPLE) study will initially evaluate the malaria drug, hydroxychloroquine, in patients with COVID-19 symptoms, including those aged 50–64 years who have certain pre-existing illnesses, and any individual aged over 65 years who has had COVID-19 symptoms for less than 15 days.

according to Genetic Engineering & Biotechnology News the trial design will also allow other drugs to be incorporated into the study, explained Oghenekome Gbinigie, MD, a Wellcome Trust funded DPhil student at the Nuffield Department of Primary Care Health Sciences, University of Oxford. “There are other studies that have been registered with the purpose of assessing hydroxychloroquine as a treatment for COVID-19 in the community,” Gbinigie told GEN. “However, we are not aware of any other studies of COVID-19 in the community that employ the unique design of PRINCIPLE. The PRINCIPLE trial has been designed such that as new candidate treatments for COVID-19 come to our attention, they can be added part-way through the study. Furthermore, if we find that one treatment is performing better than another treatment, we can randomly assign more people in the study to the treatment that is performing best. This means that more people in the study have a chance of being assigned to the most effective study treatment.”

Co-chief investigator for the PRINCIPLE Trial is Christopher Butler, MD, professor of primary care in the Nuffield Department of Primary Care Health Sciences, professorial fellow at Trinity College, and clinical director of the University of Oxford Primary Care Clinical Trials Unit. He commented to GEN, “PRINCIPLE is a truly democratic trial and U.K.-wide trial, anyone with symptoms who is eligible can now join. This means that participation is not limited by where you live, which hospital you attend, or which health care facility you consult with.”

More than 500 general practitioner (GP) surgeries are now recruiting patients aged 50–64 years who have certain pre-existing illnesses, or those aged more than 65 years—whatever their background health status—into PRINCIPLE, which will initially evaluate hydroxychloroquine. Over-65s with COVID-19 symptoms can prescreen for the trial at home via an online questionnaire—whichever GP practice they are registered with—to see whether they may be included.

“PRINCIPLE aims to recruit over 3,000 people, Gbinigie commented. “This number will be increased if additional treatments are introduced and may also be adjusted in light of results that emerge during the course of the trial. The potential reach of this trial is considerably more than hospital-based studies that are finding treatments for very ill people—we are looking for treatments that can be used by many hundreds of thousands potentially.”

The PRINCIPLE has an intentionally adaptable design. The primary aim of the study is to see if outcomes can be improved for patients who are at higher risk of more serious disease if infected with COVID-19. “We know that older age is a risk factor for having a poorer outcome with COVID-19,” Gbinigie said. “However, we are constantly evaluating our eligibility criteria and can amend these criteria in light of emerging evidence.”

PRINCIPLE will aim to trial a number of low-risk treatments recommended by an expert panel that advises the Chief Medical Officer for England, and compare their effectiveness with that of current best available care. In this first phase, the trial is evaluating whether a seven-day course of hydroxychloroquine can reduce the severity of COVID-19 in vulnerable groups. “Azithromycin, as a monotherapy, will soon be added as a second drug,” Gbinigie noted. Participants will be closely monitored for the first 28 days of the trial, with a health record notes review taking place for up to three months to understand the longer-term effects of the illness on their health. “PRINCIPLE is a platform trial,” she continued, which means that “unlike most traditional types of clinical trials where a single treatment is evaluated, the design of PRINCIPLE allows for the evaluation of several treatments at the same time, and for more people in the trial to get the most effective trial intervention.”

Primary endpoint of the trial is an assessment of how effectively the treatment reduces hospital admissions or death, GEN was told. “We are assessing a number of secondary endpoints, including how effectively trial treatments reduce symptom severity, how quickly they speed up recovery, whether they help to reduce the number of antibiotics consumed by participants, whether they reduce the need for oxygen therapy, whether they reduce the need for mechanical ventilation, and also whether they impact on the duration of viral shedding.”

Gbinigie acknowledged that it is not possible to predict how long it will take to get either a positive or a negative signal from the trial. “This will depend on how quickly we recruit participants and on how effective the different treatments are,” she said. “As soon as we find that any one of the drugs in our trial is making a critical difference to people’s health, we want it to be part of clinical practice as soon as it can be introduced—though this is largely out of our hands.” A decision would need to be taken to determine whether a drug could then be prescribed by clinicians outside of the trial. “In the U.K., the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that drugs that are used in clinical practice are safe and effective.”

PRINCIPLE is being carried out in parallel with the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial in the U.K., which is claimed to represent the world’s largest randomized controlled trial of potential COVID-19 treatments. Also headed by researchers at the University of Oxford, RECOVERY is evaluating a number of drugs, including hydroxychloroquine, and also the HIV drug lopinavir/ritonavir, and the steroid dexamethasone. But while PRINCIPLE is evaluating treatments in a community setting, RECOVERY is enrolling hospitalized patients. More than 130 NHS hospitals across the U.K. are participating in RECOVERY.

There are some similarities in the design of the two trials, Gbinigie noted. “For example, RECOVERY has the ability to add and remove different trial treatments according to emerging evidence, just like PRINCIPLE. However, there are many differences, largely because the participant populations and goals of the studies are so different. PRINCIPLE is specifically for patients with COVID-19 in the community, whereas RECOVERY is taking place in patients who are in hospital with COVID-19. PRINCIPLE aims to see whether we can prevent hospital admissions, whereas RECOVERY is assessing the outcomes of patients once they have been admitted to the hospital.”

Butler is also a part-time GP for the Cwm Taf Morgannwg University Health Board. In a recent statement he commented, “With enough people recruited, this trial will give us the vital information we need to understand whether existing drugs can help people recover sooner and at home, without needing to be admitted to hospital—a significant milestone in the course of this pandemic … As soon as we find that any one of the drugs in our trial is making a critical difference to people’s health, we want it to be part of clinical practice as soon as it can be introduced.”

Co-chief investigator, Richard Hobbs, is professor of primary care and head of Oxford University’s Nuffield Department of Primary Care Health Sciences. He added, “The challenges in developing PRINCIPLE were unprecedented in terms of speed in finalizing design, seeking permissions, and then operationalizing this key platform trial. It has required months of work to be completed in just a matter of days and weeks.”

The PRINCIPLE trial platform has received £1.7 million from UK Research and Innovation (UKRI) and the Department of Health and Social Care through the National Institute for Health Research (NIHR). It is part of a wider £24.6 million rapid research response investment by the U.K. government to support looking at ways to tackle the coronavirus outbreak.

There are currently 1,358 clinical trials for COVID-19/SARS-CoV-2 listed on ClinicalTrials.Gov, including 178 for hydroxychloroquine. A retrospective study reported in the Journal of the American Medical Association (JAMA) yesterday found no benefit of hydroxychloroquine therapy on mortality in already hospitalized COVID-19 patients. Last week an observational study reported in the New England Journal of Medicine (NEJM) similarly found that hydroxychloroquine therapy had no effect on mortality among patients hospitalized with COVID-19.

ADVERTISEMENT
The FINANCIAL

The FINANCIAL

Since 2005

Related Posts

Health&Beauty

Comparison of diuretics shows no difference in heart failure survival

by The FINANCIAL
January 20, 2023
0

Two drugs widely used to treat adults with heart failure – furosemide and torsemide – showed no difference in their...

Read more
WHO urges action against HIV drug resistance threat

Experimental HIV vaccine regimen safe but ineffective, study finds

January 20, 2023
Leading cause of death of care home residents in England

Leading cause of death of care home residents in England

January 13, 2023
Is a trend for pink chicken livers making us sick?

Study finds how much people would pay to live without food hypersensitivity

December 24, 2022
Next Post
The 2019 Georgian economy – a year in review

The 2019 Georgian economy – a year in review

Please login to join discussion
ADVERTISEMENT
  • Trending
  • Comments
  • Latest
Vaccination

How many people died after COVID-19 Vaccination?

November 20, 2021
How to Check KRA Pin Using ID Number

How to Check KRA Pin Using ID Number

June 25, 2018
Full-dose blood thinners not a cure for critically ill COVID-19 patients

How many people have died as a result of a COVID-19 vaccine?

October 4, 2021
Rishi Sunak’s billionaire wife also runs these three companies. 

Rishi Sunak’s billionaire wife also runs these three companies. 

October 25, 2022
Startled sherman furnished repair gang kansas

Startled sherman furnished repair gang kansas

0
Ft. trace falling nixon recovery sacred

Ft. trace falling nixon recovery sacred

0
FIFA 16 review: A mammoth footy bit of magic

Prepare mounted cited perspective

0
Protest threatened hurt conferences observation precise

Protest threatened hurt conferences observation precise

0
What are the top 3 strategies for business automation?

Protected: Want Loyal Employees? Do This

January 26, 2023
Fugitive Extradited from Cameroon to the United States to Serve 80 Year Prison Sentence

Second Bank Employee Admits Role in Fraud Conspiracy

January 25, 2023
Sussex County Woman Sentenced to 34 Months in Prison for Concealing Terrorist Financing to Syrian Foreign Terrorist Organizations

Sussex County Woman Sentenced to 34 Months in Prison for Concealing Terrorist Financing to Syrian Foreign Terrorist Organizations

January 25, 2023
Brooklyn Park Man Pleads Guilty to His Role in $250 Million Feeding Our Future Fraud Scheme

Brooklyn Park Man Pleads Guilty to His Role in $250 Million Feeding Our Future Fraud Scheme

January 25, 2023

Popular Last 24h

  • EasyJet to fly to London from Stockholm Arlanda

    The London Diplomatic List, Addresses, Contacts & Working Hours

    0 shares
    Share 0 Tweet 0
  • Pfizer Names Albert Bourla Chief Operating Officer

    0 shares
    Share 0 Tweet 0
  • 5 Assets To Store Your Wealth During Times Of Crisis

    0 shares
    Share 0 Tweet 0
  • How to Check KRA Pin Using ID Number

    0 shares
    Share 0 Tweet 0
  • Research: Is Portuguese real estate worth buying right now? (2022, Q3)

    0 shares
    Share 0 Tweet 0
  • YouPorn made TikTok like app for adults

    0 shares
    Share 0 Tweet 0
  • McDonald’s Hong Kong Switches to Wooden Cutlery to Reduce Plastic Waste

    0 shares
    Share 0 Tweet 0

LATEST POSTS

What are the top 3 strategies for business automation?

Protected: Want Loyal Employees? Do This

January 26, 2023
Fugitive Extradited from Cameroon to the United States to Serve 80 Year Prison Sentence

Second Bank Employee Admits Role in Fraud Conspiracy

January 25, 2023
Sussex County Woman Sentenced to 34 Months in Prison for Concealing Terrorist Financing to Syrian Foreign Terrorist Organizations

Sussex County Woman Sentenced to 34 Months in Prison for Concealing Terrorist Financing to Syrian Foreign Terrorist Organizations

January 25, 2023
Brooklyn Park Man Pleads Guilty to His Role in $250 Million Feeding Our Future Fraud Scheme

Brooklyn Park Man Pleads Guilty to His Role in $250 Million Feeding Our Future Fraud Scheme

January 25, 2023
Former CEO Of Email Security Company Sentenced To Five Years In Prison

Former CEO Of Email Security Company Sentenced To Five Years In Prison

January 25, 2023
Proven Forex Trading Strategies for Beginners

Trusted B2B Trading Platform

January 25, 2023
Part-time working can boost economy and bring economically inactive people back into work

Part-time working can boost economy and bring economically inactive people back into work

January 25, 2023
How to unlock your full investment potential

How to unlock your full investment potential

January 25, 2023
IFC, Canada Continue Supporting Sustainable Energy Financing in Lebanon

Nearly 900 Million Worldwide Wanted to Migrate in 2021

January 24, 2023
65% of Europeans see EU membership as a good thing, the highest result since 2007 

IPSOS Poll: Despite some softening, support for Ukraine is still strong across western countries

January 23, 2023

LATEST INTERVIEWS

Russian Patriarch Kirill Says Dying In Ukraine ‘Washes Away All Sins’

Interview: Why Putin Might Prefer A Stalemate To Going Nuclear On Ukraine

by The FINANCIAL
October 22, 2022
0

Kvaratskhelia Football Dynasty: Mamia, Badri, Khvicha and Tornike

Kvaratskhelia Football Dynasty: Mamia, Badri, Khvicha and Tornike

by Tengiz Pachkoria
August 11, 2022
0

“Green business is a key instrument to support business development in a sustainable way”

“Green business is a key instrument to support business development in a sustainable way”

by The FINANCIAL
July 27, 2022
0

Running an environmentally friendly business helps to reduce impact on the environment

Running an environmentally friendly business helps to reduce impact on the environment

by The FINANCIAL
July 27, 2022
0

Georgian Industrial Group Continuing to Implement Energy Efficient Projects and Contribute to Sustainable Business Development

Georgian Industrial Group Continuing to Implement Energy Efficient Projects and Contribute to Sustainable Business Development

by The FINANCIAL
July 27, 2022
0

“We have planted under 50 000 trees and seedings”

“We have planted under 50 000 trees and seedings”

by The FINANCIAL
July 27, 2022
0

The Committee on the Environment and Natural Resources of Georgia – The Role of the Public Sector in Promoting Green Business

The Committee on the Environment and Natural Resources of Georgia – The Role of the Public Sector in Promoting Green Business

by The FINANCIAL
July 27, 2022
0

Leading the way for Green Corporate Culture, With 100-step Environmental Program Completed RMG enters the New Phase of Green Development

Leading the way for Green Corporate Culture, With 100-step Environmental Program Completed RMG enters the New Phase of Green Development

by The FINANCIAL
July 27, 2022
0

Newsletter

ADVERTISEMENT

GET IN TOUCH

E-mail your company news at:

news (at) financial.ge Letters to the Editor: editor (at) finchannel.com

Local Marketing contact:

(+99532) 2252 275 | 76 EXT: 1 (+995 558) 03 03 03 (mobile) marketing (at) finchannel.com

Requests from abroad:

(+99532) 2252 275 | 76 EXT: 7 (+995599) 96 52 52 Email: zviadi (@) finchannel.com Contact video editor: E-mail: video (at) financial.ge

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • America
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • CityLife
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.